Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cibus, Inc.CBUS · Entity 6658 | Director | June 02, 2026 | June 04, 2026 |
| KYNTRA BIO, INC.FGEN · Entity 7431 | Director | May 26, 2021 | May 28, 2021 |
| Royalty Pharma plcRPRX · Entity 3100 | Director | February 20, 2024 | February 23, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cibus, Inc.
Report date June 02, 2026 · Filed June 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right-to-Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.39 · Expires 2036-06-02 | Direct | 77,586 |
Reported balance
After 2026-06-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-02 · Grant · Acquired 77,586 · Balance 77,586 F1: The Options vest in full, subject to the Director's continued service, the earlier of (1) the first anniversary of the grant date and (2) the date of the Company's next annual meeting of shareholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The Options vest in full, subject to the Director's continued service, the earlier of (1) the first anniversary of the grant date and (2) the date of the Company's next annual meeting of shareholders.
KYNTRA BIO, INC.
Report date May 26, 2021 · Filed May 28, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 395,750 |
Reported balance
After 2021-05-26 transaction · row 1
1 source rowRow 1 · 2021-05-26 · Grant · Acquired 4,700 · Balance 395,750 F1: Represents the grant of restricted stock units that vest on the earlier of May 26, 2022 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.86 · Expires 2031-05-25 | Direct | 7,800 |
Reported balance
After 2021-05-26 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-05-26 · Grant · Acquired 7,800 · Balance 7,800 F3: Options vest on the earlier of May 26, 2022 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 605,713 |
Reported balance
Holding disclosure · report date 2021-05-26 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 605,713 F2: Shares are held by New Ventures I, LLC. The reporting person is Managing Member of New Ventures I, LLC and has voting and investment control with respect to the shares held by New Ventures I, LLC. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the grant of restricted stock units that vest on the earlier of May 26, 2022 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date.
F2: Shares are held by New Ventures I, LLC. The reporting person is Managing Member of New Ventures I, LLC and has voting and investment control with respect to the shares held by New Ventures I, LLC.
F3: Options vest on the earlier of May 26, 2022 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date.
Royalty Pharma plc
Report date February 20, 2024 · Filed February 23, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Ordinary SharesSEC Table I · non-derivative | Direct | 320,099 |
Reported balance
After 2024-02-20 transaction · row 1
1 source rowRow 1 · 2024-02-20 · Conversion · Acquired 300,000 · Balance 320,099 F1: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange. |
| LP interests in RPI US Partners 2019, LPSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 270,000 |
Reported balance
After 2024-02-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-02-20 · Conversion · Disposed 30,000 · Balance 270,000 F1: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange. F2: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value. |
| Class A Ordinary SharesSEC Table I · non-derivative | IndirectBy New Ventures III LLC | 85,187 |
Reported balance
Holding disclosure · report date 2024-02-20 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 85,187 |
| Class A Ordinary SharesSEC Table I · non-derivative | IndirectBy Spouse | 15,000 |
Reported balance
Holding disclosure · report date 2024-02-20 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 15,000 |
Filing footnotes · ownership attribution and instrument terms
F1: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange.
F2: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Intra-Cellular Therapies, Inc.
Report date April 02, 2025 · Filed April 02, 2025
Section 16 reporting ended · disclosed 2025-04-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-04-02 transaction · row 1
1 source rowRow 1 · 2025-04-02 · Disposition to issuer · Disposed 131,512 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 10, 2025 (the "Merger Agreement"), by and among Intra-Cellular Therapies, Inc. (the "Company"), Johnson & Johnson, a New Jersey corporation ("Parent"), and Fleming Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which, subject to the terms and conditions thereof, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent, effective as of April 2, 2025 (the "Effective Time"). F2: (Continued from Footnote 1) At the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Company Shares") issued and outstanding immediately prior to the Effective Time (other than certain Company Shares canceled pursuant to the Merger Agreement and Company Shares with respect to which appraisal rights had been properly and validly exercised) was automatically converted into the right to receive an amount equal to $132.00 per share in cash (the "Merger Consideration"), without interest thereon and less any applicable tax withholdings. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.58 · Expires 2025-06-15 | Direct | 0 |
Reported balance
After 2025-04-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-04-02 · Disposition to issuer · Disposed 20,000 · Balance 0 F3: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. F4: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.35 · Expires 2026-06-13 | Direct | 0 |
Reported balance
After 2025-04-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-04-02 · Disposition to issuer · Disposed 20,000 · Balance 0 F3: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. F4: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.45 · Expires 2027-06-26 | Direct | 0 |
Reported balance
After 2025-04-02 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-04-02 · Disposition to issuer · Disposed 20,000 · Balance 0 F3: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. F4: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.45 · Expires 2031-06-20 | Direct | 0 |
Reported balance
After 2025-04-02 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-04-02 · Disposition to issuer · Disposed 20,000 · Balance 0 F3: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. F4: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $55.48 · Expires 2032-06-08 | Direct | 0 |
Reported balance
After 2025-04-02 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-04-02 · Disposition to issuer · Disposed 16,757 · Balance 0 F3: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. F4: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $63.79 · Expires 2033-06-22 | Direct | 0 |
Reported balance
After 2025-04-02 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-04-02 · Disposition to issuer · Disposed 7,009 · Balance 0 F3: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. F4: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $67.77 · Expires 2034-06-13 | Direct | 0 |
Reported balance
After 2025-04-02 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2025-04-02 · Disposition to issuer · Disposed 4,322 · Balance 0 F3: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. F4: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-04-02 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2025-04-02 · Disposition to issuer · Disposed 2,951 · Balance 0 F5: Each restricted stock unit (each, a "Company RSU") represented a contingent right to receive one Company Share. F6: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company RSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company RSU immediately prior to the Effective Time and (ii) the Merger Consideration. Notwithstanding the foregoing, in the case of each Company RSU granted in 2025, the Merger Consideration will instead be payable at the time the original Company RSU would have vested, subject to accelerated vesting in certain circumstances. F7: Not applicable. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 10, 2025 (the "Merger Agreement"), by and among Intra-Cellular Therapies, Inc. (the "Company"), Johnson & Johnson, a New Jersey corporation ("Parent"), and Fleming Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which, subject to the terms and conditions thereof, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent, effective as of April 2, 2025 (the "Effective Time").
F2: (Continued from Footnote 1) At the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Company Shares") issued and outstanding immediately prior to the Effective Time (other than certain Company Shares canceled pursuant to the Merger Agreement and Company Shares with respect to which appraisal rights had been properly and validly exercised) was automatically converted into the right to receive an amount equal to $132.00 per share in cash (the "Merger Consideration"), without interest thereon and less any applicable tax withholdings.
F3: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option.
F4: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration.
F5: Each restricted stock unit (each, a "Company RSU") represented a contingent right to receive one Company Share.
F6: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company RSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company RSU immediately prior to the Effective Time and (ii) the Merger Consideration. Notwithstanding the foregoing, in the case of each Company RSU granted in 2025, the Merger Consideration will instead be payable at the time the original Company RSU would have vested, subject to accelerated vesting in certain circumstances.
F7: Not applicable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 30, 2018 Filed Apr 3, 2018 20:31 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | GrantCommon Stock | 688 | $21.05 | $14,482.40 |
DisclosureSEC source: 0001209191-18-022975 · doc4.xml · nonDerivative · entry 1 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,296 Read SEC document |
| March 13, 2018 Filed Mar 15, 2018 00:19 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 2,618 | $55.19 | $144,487.42 |
DisclosureSEC source: 0001209191-18-019708 · doc4.xml · nonDerivative · entry 4 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 379,200 F4 · price: The shares were sold at prices ranging from $55.00 to $55.85. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price Read SEC document |
| March 13, 2018 Filed Mar 15, 2018 00:19 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 4,382 | $54.90 | $240,571.80 |
DisclosureSEC source: 0001209191-18-019708 · doc4.xml · nonDerivative · entry 3 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 381,818 F3 · price: The shares were sold at prices ranging from $54.80 to $54.95. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 13, 2018 Filed Mar 15, 2018 00:19 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 5,402 | $53.07 | $286,684.14 |
DisclosureSEC source: 0001209191-18-019708 · doc4.xml · nonDerivative · entry 2 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 386,200 F2 · price: The shares were sold at prices ranging from $53.00 to $53.15. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 12, 2018 Filed Mar 15, 2018 00:19 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 19,693 | $54.98 | $1,082,721.14 |
DisclosureSEC source: 0001209191-18-019708 · doc4.xml · nonDerivative · entry 1 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 391,602 F1 · price: The shares were sold at prices ranging from $54.90 to $55.10. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 09, 2018 Filed Mar 10, 2018 00:48 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 22,905 | $55.75 | $1,276,953.75 |
DisclosureSEC source: 0001209191-18-018646 · doc4.xml · nonDerivative · entry 1 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 411,295 F1 · price: The shares were sold at prices ranging from $55.50 to $56.20. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 29, 2017 Filed Jan 3, 2018 21:31 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | PurchaseCommon Stock | 1,001 | $14.48 | $14,494.48 |
DisclosureSEC source: 0001209191-18-000895 · doc4.xml · nonDerivative · entry 1 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,608 Read SEC document |
| December 29, 2017 Filed Jan 3, 2018 23:05 UTC Amendment | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | GrantCommon Stock | 1,001 | $14.48 | $14,494.48 |
DisclosureSEC source: 0001209191-18-001226 · doc4a.xml · nonDerivative · entry 1 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,608 Read SEC document |
| December 15, 2017 Filed Feb 15, 2018 01:07 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GiftCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-010201 · doc5.xml · nonDerivative · entry 1 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 434,200 Read SEC document |
| September 29, 2017 Filed Oct 3, 2017 22:17 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | GrantCommon Stock | 918 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-055385 · doc4.xml · nonDerivative · entry 1 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,607 Read SEC document |
| September 13, 2017 Filed Sep 15, 2017 22:38 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 25,000 | $51.92 | $1,298,000.00 |
DisclosureSEC source: 0001209191-17-053056 · doc4.xml · nonDerivative · entry 1 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 435,200 F1 · price: The shares were sold at prices ranging from $51.50 to $52.30. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 22:05 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | GrantCommon Stock | 1,167 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-043566 · doc4.xml · nonDerivative · entry 1 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,689 Read SEC document |
| June 27, 2017 Filed Jun 29, 2017 20:24 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $12.45 | $0.00 |
DisclosureSEC source: 0001209191-17-042295 · doc4.xml · derivative · entry 1 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-06-27 Read SEC document |
| June 07, 2017 Filed Jun 9, 2017 22:40 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $28.65 | $0.00 |
DisclosureSEC source: 0001209191-17-039000 · doc4.xml · derivative · entry 1 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2027-06-07 F1 · derivative.exercise_date: The shares subject to the option vest and become exercisable quarterly over one year measured from June 7, 2017. Read SEC document |
| March 31, 2017 Filed Apr 4, 2017 20:54 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | GrantCommon Stock | 892 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-024963 · doc4.xml · nonDerivative · entry 1 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,522 Read SEC document |
| December 30, 2016 Filed Jan 3, 2017 21:31 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | GrantCommon Stock | 960 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-000249 · doc4.xml · nonDerivative · entry 1 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,630 Read SEC document |
| December 16, 2016 Filed Dec 16, 2016 23:54 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 20,000 | $20.87 | $417,310.00 |
DisclosureSEC source: 0001209191-16-155725 · doc4.xml · nonDerivative · entry 1 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 460,200 F1 · price: The shares were sold at prices ranging from $20.7334 to $21.1466. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 30, 2016 Filed Oct 4, 2016 20:44 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | GrantCommon Stock | 951 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-144334 · doc4.xml · nonDerivative · entry 1 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,670 Read SEC document |
| December 12, 2002 Filed Dec 13, 2022 23:20 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 40,010 | $41.98 | $1,679,683.82 |
DisclosureSEC source: 0001209191-22-061057 · doc4.xml · nonDerivative · entry 2 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,712 F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.90 to $42.07 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.